Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Herceptin
Herceptin 150 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 9
HOS-090903 · Präparat HOS-084155
Data from study JP16003, a single-arm study of Herceptin (4 mg/kg IV loading dose and 2 mg/kg IV
weekly) and docetaxel (60 mg/m2 IV) in Japanese women with HER2- positive MBC, suggested that
concomitant administration of Herceptin had no effect on the single dose pharmacokinetics of
docetaxel. Study JP19959 was a substudy of BO18255 (ToGA) performed in male and female
Japanese patients with advanced gastric cancer to study the pharmacokinetics of capecitabine and
cisplatin when used with or without Herceptin. The results of this substudy suggested that the
exposure to the bioactive metabolites (e.g. 5-FU) of capecitabine was not affected by concurrent use of
cisplatin or by concurrent use of cisplatin plus Herceptin. However, capecitabine itself showed higher
concentrations and a longer half-life when combined with Herceptin. The data also suggested that the
pharmacokinetics of cisplatin were not affected by concurrent use of capecitabine or by concurrent use
of capecitabine plus Herceptin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisplatin (HOS-086022) docetaxel (HOS-084505) capecitabine (HOS-090904)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-25T17:43:00Z · SHA-256 4737cd7c26cd2805fc40be61983542b3a3127abbce7e3ca6ebc3b5c0895dda53 · Passage a93c204c81ec5f58911cd3af5f32bc3a7049d0beec0577a8026374dcf36e5639 · Zeichen 864–1869 im Abschnitt
Wechselwirkungen · Herceptin
Herceptin 600 mg solution for injection in vial · Abschnitt 4.5 · PDF-Seite 40
HOS-090952 · Präparat HOS-084155
Data from study JP16003, a single-arm study of Herceptin (4 mg/kg IV loading dose and 2 mg/kg IV
weekly) and docetaxel (60 mg/m2 IV) in Japanese women with HER2- positive MBC, suggested that
concomitant administration of Herceptin had no effect on the single dose pharmacokinetics of
docetaxel. Study JP19959 was a substudy of BO18255 (ToGA) performed in male and female
Japanese patients with advanced gastric cancer to study the pharmacokinetics of capecitabine and
cisplatin when used with or without Herceptin. The results of this substudy suggested that the
exposure to the bioactive metabolites (e.g. 5-FU) of capecitabine was not affected by concurrent use of
cisplatin or by concurrent use of cisplatin plus Herceptin. However, capecitabine itself showed higher
concentrations and a longer half-life when combined with Herceptin. The data also suggested that the
pharmacokinetics of cisplatin were not affected by concurrent use of capecitabine or by concurrent use
of capecitabine plus Herceptin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisplatin (HOS-086022) docetaxel (HOS-084505) capecitabine (HOS-090904)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-25T17:43:00Z · SHA-256 4737cd7c26cd2805fc40be61983542b3a3127abbce7e3ca6ebc3b5c0895dda53 · Passage a93c204c81ec5f58911cd3af5f32bc3a7049d0beec0577a8026374dcf36e5639 · Zeichen 864–1869 im Abschnitt
Wechselwirkungen · Avastin
Avastin 25 mg/ml concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 9
HOS-113526 · Präparat HOS-093945
Effect of antineoplastic agents on bevacizumab pharmacokinetics
No clinically relevant interaction of co-administered chemotherapy on bevacizumab pharmacokinetics
was observed based on the results of population pharmacokinetic analyses. There were neither
statistically significant nor clinically relevant differences in bevacizumab clearance in patients
receiving Avastin monotherapy compared to patients receiving Avastin in combination with interferon
alfa-2a, erlotinib or chemotherapies (IFL, 5-FU/LV, carboplatin/paclitaxel, capecitabine, doxorubicin
or cisplatin/gemcitabine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): gemcitabine (HOS-113530) cisplatin (HOS-086022) carboplatin (HOS-084540) erlotinib (HOS-113527) capecitabine (HOS-090904) paclitaxel (HOS-087959) doxorubicin (HOS-084538)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T12:02:00Z · SHA-256 66d06bf8e8d4853783377bc4046bd6b4b0e313cc348c230743646f93a9381bb1 · Passage f07e1107be8ab49b06345bf1a1ff7a26e7af59eb51f28bf857d3bf10002fe20c · Zeichen 0–583 im Abschnitt
Wechselwirkungen · Avastin
Avastin 25 mg/ml concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 9
HOS-113531 · Präparat HOS-093945
Effect of bevacizumab on the pharmacokinetics of other antineoplastic agents
No clinically relevant interaction of bevacizumab was observed on the pharmacokinetics of co-
administered interferon alfa 2a, erlotinib (and its active metabolite OSI-420), or the chemotherapies
irinotecan (and its active metabolite SN38), capecitabine, oxaliplatin (as determined by measurement
of free and total platinum), and cisplatin. Conclusions on the impact of bevacizumab on gemcitabine
pharmacokinetics cannot be drawn.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): platinum (HOS-086055) gemcitabine (HOS-113530) cisplatin (HOS-086022) erlotinib (HOS-113527) capecitabine (HOS-090904) oxaliplatin (HOS-091432) irinotecan (HOS-112102)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T12:02:00Z · SHA-256 66d06bf8e8d4853783377bc4046bd6b4b0e313cc348c230743646f93a9381bb1 · Passage 1745c8059a824a1b14465bffa2bc20de6cced92c506d2029e0bcf7b8fcd615af · Zeichen 585–1092 im Abschnitt
Wechselwirkungen · Nexavar
Nexavar 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-115764 · Präparat HOS-094353
In clinical studies sorafenib has been administered with a variety of other anti-neoplastic agents at
their commonly used dosing regimens including gemcitabine, cisplatin, oxaliplatin, paclitaxel,
carboplatin, capecitabine, doxorubicin, irinotecan, docetaxel and cyclophosphamide. Sorafenib had no
clinically relevant effect on the pharmacokinetics of gemcitabine, cisplatin, carboplatin, oxaliplatin or
cyclophosphamide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): gemcitabine (HOS-113530) cisplatin (HOS-086022) docetaxel (HOS-084505) carboplatin (HOS-084540) capecitabine (HOS-090904) cyclophosphamide (HOS-084539) oxaliplatin (HOS-091432) paclitaxel (HOS-087959) doxorubicin (HOS-084538) irinotecan (HOS-112102)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-28T11:40:00Z · SHA-256 4561f7f7d54908430c2d44ab3a6a7808fbf136793e601e405c6fd3f8791d1b27 · Passage 03ec0414f3769c1553ef113f9e65bc3c47eaf9a5ef56f39d1288ca393a0c8149 · Zeichen 2815–3236 im Abschnitt
Wechselwirkungen · Javlor
Javlor 25 mg/mL concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 7
HOS-209959 · Präparat HOS-154415
In vitro studies showed that vinflunine is a Pgp-substrate like other vinca alkaloids, but with a lower
affinity. Therefore, risks of clinically significant interactions should be unlikely.
No pharmacokinetic interaction was observed in patients when vinflunine was combined with either
cisplatin, carboplatin, capecitabine or gemcitabine.
No pharmacokinetic interaction was observed in patients when vinflunine was combined with
doxorubicin. However, this combination was associated with a particularly high risk of haematological
toxicity.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): gemcitabine (HOS-113530) cisplatin (HOS-086022) carboplatin (HOS-084540) capecitabine (HOS-090904) doxorubicin (HOS-084538)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-16T16:00:00Z · SHA-256 42cf54c061848915aaf4725253c94714208299721898148bd6a0b52a0524d49c · Passage b31620d8ad7842855a78fdde25e74eaa33f4d8f6fb3baab09504b9e17098342e · Zeichen 193–734 im Abschnitt
Wechselwirkungen · Kanjinti
KANJINTI 150 mg powder for concentrate for solution for infusion KANJINTI 420 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 9
HOS-138162 · Präparat HOS-098156
Data from study JP16003, a single-arm study of trastuzumab (4 mg/kg intravenous loading dose and
2 mg/kg intravenous weekly) and docetaxel (60 mg/m2 intravenous) in Japanese women with
HER2 positive MBC, suggested that concomitant administration of trastuzumab had no effect on the
single-dose pharmacokinetics of docetaxel. Study JP19959 was a substudy of BO18255 (ToGA)
performed in male and female Japanese patients with advanced gastric cancer to study the
pharmacokinetics of capecitabine and cisplatin when used with or without trastuzumab. The results of
this substudy suggested that the exposure to the bioactive metabolites (e.g. 5-FU) of capecitabine was
not affected by concurrent use of cisplatin or by concurrent use of cisplatin plus trastuzumab.
However, capecitabine itself showed higher concentrations and a longer half-life when combined with
trastuzumab. The data also suggested that the pharmacokinetics of cisplatin were not affected by
concurrent use of capecitabine or by concurrent use of capecitabine plus trastuzumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisplatin (HOS-086022) docetaxel (HOS-084505) capecitabine (HOS-090904)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T11:54:00Z · SHA-256 64f7023b8ef470359816997a176374c724377705a011d7a85e82ff4bfbdf5d30 · Passage 7a062850acffd18c6e3ed8a2f09c22becae79551f36c25729ddfc1cf8bf4fb44 · Zeichen 883–1926 im Abschnitt
Wechselwirkungen · Trazimera
Trazimera 150 mg powder for concentrate for solution for infusion Trazimera 420 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 9
HOS-139505 · Präparat HOS-098360
Data from study JP16003, a single-arm study of trastuzumab (4 mg/kg intravenous loading dose and
2 mg/kg intravenous dose weekly) and docetaxel (60 mg/m2 intravenous dose) in Japanese women
with HER2-positive MBC, suggested that concomitant administration of trastuzumab had no effect
on the single-dose pharmacokinetics of docetaxel. Study JP19959 was a substudy of BO18255
(ToGA) performed in male and female Japanese patients with advanced gastric cancer to study the
pharmacokinetics of capecitabine and cisplatin when used with or without trastuzumab. The results
of this substudy suggested that the exposure to the bioactive metabolites (e.g. 5-FU) of capecitabine
was not affected by concurrent use of cisplatin or by concurrent use of cisplatin plus trastuzumab.
However, capecitabine itself showed higher concentrations and a longer half-life when combined
with trastuzumab. The data also suggested that the pharmacokinetics of cisplatin were not affected
by concurrent use of capecitabine or by concurrent use of capecitabine plus trastuzumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisplatin (HOS-086022) docetaxel (HOS-084505) capecitabine (HOS-090904)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-08T10:10:00Z · SHA-256 9fdaf2b6f4270ea70563d54731dd8a8b47224a5c6f4970a6433712c7e0145f3f · Passage 881b99ae7fc758cda05218d0b796dfdca115d92ed06199cdfd460a7c7d50db09 · Zeichen 888–1941 im Abschnitt
Wechselwirkungen · Mvasi
MVASI 25 mg/mL concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 10
HOS-140857 · Präparat HOS-098594
No clinically relevant interaction of co-administered chemotherapy on bevacizumab pharmacokinetics
was observed based on the results of population pharmacokinetic analyses. There were neither
statistically significant nor clinically relevant differences in bevacizumab clearance in patients
receiving bevacizumab monotherapy compared to patients receiving bevacizumab in combination with
interferon alfa-2a, erlotinib or chemotherapies (IFL, 5-FU/LV, carboplatin/paclitaxel, capecitabine,
doxorubicin or cisplatin/gemcitabine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): gemcitabine (HOS-113530) cisplatin (HOS-086022) carboplatin (HOS-084540) erlotinib (HOS-113527) capecitabine (HOS-090904) paclitaxel (HOS-087959) interferon alfa-2a (HOS-135516) doxorubicin (HOS-084538)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-08T12:03:00Z · SHA-256 7315a0f92d93f32ff51c381d8e3464645773cd3c5a1bc96a97e09c6d6939e82e · Passage df226e1c2394ae80b86c617add6af3a21067539f8cc95ac8cd6f93616bcc62f7 · Zeichen 65–592 im Abschnitt
Wechselwirkungen · Mvasi
MVASI 25 mg/mL concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 10
HOS-140867 · Präparat HOS-098594
No clinically relevant interaction of bevacizumab was observed on the pharmacokinetics of
co-administered interferon alfa-2a, erlotinib (and its active metabolite OSI-420), or the
chemotherapies irinotecan (and its active metabolite SN38), capecitabine, oxaliplatin (as determined
by measurement of free and total platinum), and cisplatin. Conclusions on the impact of bevacizumab
on gemcitabine pharmacokinetics cannot be drawn.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): platinum (HOS-086055) gemcitabine (HOS-113530) cisplatin (HOS-086022) erlotinib (HOS-113527) capecitabine (HOS-090904) oxaliplatin (HOS-091432) interferon alfa-2a (HOS-135516) irinotecan (HOS-112102)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-08T12:03:00Z · SHA-256 7315a0f92d93f32ff51c381d8e3464645773cd3c5a1bc96a97e09c6d6939e82e · Passage d85486369c5822408cafead0fd690e0a89a1618f2625516fd820cb6493788b23 · Zeichen 672–1101 im Abschnitt
Wechselwirkungen · Phesgo
Phesgo 600 mg/600 mg solution for injection Phesgo 1 200 mg/600 mg solution for injection · Abschnitt 4.5 · PDF-Seite 9
HOS-146995 · Präparat HOS-099594
Data from study JP16003, a single-arm study of trastuzumab (4 mg/kg intravenous loading dose and
2 mg/kg intravenous weekly) and docetaxel (60 mg/m2 intravenous) in Japanese women with
HER2-positive metastatic breast cancer, suggested that concomitant administration of trastuzumab had
no effect on the single dose pharmacokinetics of docetaxel. Study JP19959 was a substudy of
BO18255 (ToGA) performed in male and female Japanese patients with advanced gastric cancer to
study the pharmacokinetics of capecitabine and cisplatin when used with or without trastuzumab. The
results of this substudy suggested that the exposure to the bioactive metabolites (e.g. 5-FU) of
capecitabine was not affected by concurrent use of cisplatin or by concurrent use of cisplatin plus
trastuzumab. However, capecitabine itself showed higher concentrations and a longer half-life when
combined with trastuzumab. The data also suggested that the pharmacokinetics of cisplatin were not
affected by concurrent use of capecitabine or by concurrent use of capecitabine plus trastuzumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisplatin (HOS-086022) docetaxel (HOS-084505) capecitabine (HOS-090904)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-28T11:50:00Z · SHA-256 a6c98bf6b55eca9607a319c3be5d77798ac324754cdfd92882fd80d342fc312e · Passage 1dc560e67a455e29b404ce69db758523ac92f20f882d155d3728a839f9855c8f · Zeichen 1868–2932 im Abschnitt
Wechselwirkungen · Herwenda
Herwenda 150 mg powder for concentrate for solution for infusion Herwenda 420 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 9
HOS-149368 · Präparat HOS-100044
Data from study JP16003, a single-arm study of trastuzumab (4 mg/kg intravenous loading dose and
2 mg/kg intravenous weekly) and docetaxel (60 mg/m2 intravenous) in Japanese women with HER2
positive MBC, suggested that concomitant administration of trastuzumab had no effect on the single
dose pharmacokinetics of docetaxel. Study JP19959 was a substudy of BO18255 (ToGA) performed
in male and female Japanese patients with advanced gastric cancer to study the pharmacokinetics of
capecitabine and cisplatin when used with or without trastuzumab. The results of this substudy
suggested that the exposure to the bioactive metabolites (e.g. 5-FU) of capecitabine was not affected
by concurrent use of cisplatin or by concurrent use of cisplatin plus trastuzumab. However,
capecitabine itself showed higher concentrations and a longer half-life when combined with
trastuzumab. The data also suggested that the pharmacokinetics of cisplatin were not affected by
concurrent use of capecitabine or by concurrent use of capecitabine plus trastuzumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisplatin (HOS-086022) docetaxel (HOS-084505) capecitabine (HOS-090904)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T17:30:00Z · SHA-256 0420b6f06ca3e337d4516096fe98f47fc8d3f966fddcad79ddc2566b63477530 · Passage 094f48665d2293ae29c3f2f58ae4f28f7cbe5f1008d7589c49b71b15304e6a3f · Zeichen 886–1929 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.